The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children
The HIV Netherlands Australia Thailand Research Collaboration
Information provided by (Responsible Party)
The HIV Netherlands Australia Thailand Research Collaboration
First received: June 4, 2010
Last updated: June 4, 2010
Last Verified: June 2010
History of Changes
To study about the immunogenicity, safety and efficacy of varicella-zoster virus vaccine in HIV-infected children.
Biological : VZV vaccination
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
|Official Title:||The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children|
Further study details as provided by The HIV Netherlands Australia Thailand Research Collaboration:
Primary Outcome Measures
- Proportion of children with protective VZV Antibody in HIV infected children after 2 doses of VZV vaccine. [ Time Frame: 1 month after vaccine completion ]
- Adverse events from VZV vaccine. [ Time Frame: 1 month after completion of vaccine ]
- Compare proportion of children who developed VZV antibody by baseline characteristics e.g. immune status, age, gender. [ Time Frame: 1 month after completion of vaccine ]
|Study Start Date:||June 2009|
|Study Completion Date:||August 2009|
|Primary Completion Date:||August 2009 (Final data collection date for primary outcome measure)|
Receive 1 course of VZV vaccine : 2 doses of vaccines with 3 months apart.
Dose : 0.5 ml Route : subcutaneous injection (SC)
VZV causes two clinical diseases, primary infection results in varicella (chickenpox) after
which virus latent in dorsal root ganglion. Reactivation of VZV results in herpes zoster
(shingles) about years or decades. Immunocompetent children, varicella generally mild self
limiting illness. In HIV infected children, VZV is often more severe illness with progressive
varicella characterized by continuing eruption of lesions and high fever persist into second
weeks, as well as encephalitis, hepatitis and pneumonia can developed. Zoster in
immunocompromised patient become disseminated with lesions appearing outsides primary
dermatomes and with visceral complications and can cause recurrences of herpes zoster. VZV
illness in patients with immunodeficiency disorders require admission to hospital and the use
of antiviral drugs. Sometimes, antiviral drug fails in immunocompromised children. Passive
immunization with varicella zoster-immunoglobulin (VZIG), administered within three days of
exposure, is effective in preventing disease or in reducing severity of illness in
susceptible immunocompromised persons. About half of the cases of varicella in
immunocompromised children occur without a recognised exposure to VZV. Both severe and fatal
varicella has been documented despite appropriate immunoprophylaxis withVZIG. Furthermore,
VZIG is expensive and short supply. These limitations make passive immunization a less than
optimum strategy for preventing chickenpox. Permanent protection provided by administering
the vaccine to high-risk persons would be preferable.
Sartori AM., University of Sao Paolo in Sep 2004 found that after give two doses of the varicella vaccine in 41 susceptible HIV-infected childrens in CDC class N1 or A1. Seroconversion occurred in 53% and 60% of vaccines after one and two doses, respectively. No significant fall in CD4 T lymphocytes or increase in HIV viral load at eight weeks after vaccination.
Saro H. Armenian, University of Southern California in Nov 2005 administrated single dose of live varicella vaccine to 10 HIV infected children. After vaccination, positive VZV-LPA response was detected in 50% of patients at week 2 and 100% at week 4, remained positive in 90% at week 52. VZV IgG was detected in 11% at week 2, 67% at week 8, only 33% at week 52.
Myron J. Levin, University of Colorado in June 2006-2008 study about the safety and immunogenicity of vaccine in varicella-zoster virus (VZV) naive, HIV-infected children with moderate symptoms and/or more pronounced past or current decreases in CD4+ T cell counts. Recipients (97 children) were stratified into 3 groups : group I - CDC category 1 and immunologic category 1 (least affected group of HIV-infected children), group II - CDC category A, B, or N and immunologic category 2 (CD4% = 15-24), group III : CDC category C and/or immunologic category 3, but at least 3 months prior to vaccination, had achieved clinical category A or N and equivalent of immunologic category 1 (CD4% = 25). After 2 doses of vaccines , 79% of children developed VZV-specific antibody and/or CMI 2 months after vaccine and 83% were responders 1 year after vaccination. Bekker V., Emma Children's Hospital, Netherland in Nov 2006 administered 2 doses of varicella vaccine to 15 VZV-seronegative HIV-1 infected children (total lymphocyte counts > 700 lymphocytes/microl) and 6 HIV-negative VZV-seronegative. Only 60% of the HIV-1 infected children had VZV-specific Ab after two immunizations, where as 100% of the siblings seroconverted.
Thai HIV infected children usually start antiretroviral late due to limited access to care with more severe suppressed of immune status than children in developed countries. Moreover, VZV vaccine is not in the country guideline and still expensive. We would like to provide VZV prevention for this group of children and to evaluate the VZV antibody response in Thai HIV children after VZV vaccination.
|Ages Eligible for Study:||1 Year to 15 Years|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- HIV-infected children.
- Aged between 1 to 15 years.
- CD4 T lymphocyte percentage ≥ 15% or ≥ 200 cell/ml within 6 months at time of enrollment.
- Written informed consent was obtained from each child's parent or guardian before enrollment.
- HIV-infected children who age more than 7 years old sign assent.
- History of clinical varicella or zoster.
- History of exposure to VZV within 1 month before study entry.
- Received varicella vaccine.
- Received immunoglobulin or blood product within 3 months before study entry.
- Using oral steroid or immunosuppressive drugs within 3 months before study entry.
- History of hypersensitivity to vaccine component (Neomycin).
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01138215
Locations Show More
|Department of Pediatrics, Chulalongkorn University|
|Bangkok, Thailand, 10330|
Sponsors and CollaboratorsThe HIV Netherlands Australia Thailand Research Collaboration
Additional Information:HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
|Responsible Party:||Thanyawee Puthanakit, HIV-NAT|
|ClinicalTrials.gov Identifier:||NCT01138215 History of Changes|
|Other Study ID Numbers:||HIV-NAT 111|
|Study First Received:||June 4, 2010|
|Last Updated:||June 4, 2010|
Keywords provided by The HIV Netherlands Australia Thailand Research Collaboration:varicella-zoster virus vaccine
varicella-zoster virus antibody
safety and efficacy
Assess protective VZV Antibody
Adverse events from VZV vaccine
Additional relevant MeSH terms:
ClinicalTrials.gov processed this data on November 15, 2018
This information is provided by ClinicalTrials.gov.